论文部分内容阅读
目的了解控制达标的2型糖尿病患者用药情况,为临床合理用药提供参考。方法对334例糖化血红蛋白(HbA_(lc))≤6.5%的2型糖尿病患者行空腹血糖、C肽测定,同时调查糖尿病药物用药情况,对药物的分布及频率进行分析。结果 334例HbA_(lc)达标的患者中,使用频率最高的药物是糖苷酶抑制剂(49.7%)。全部患者中有56.6%(189/334)进行了联合用药。最常见的联合用药方案是:预混胰岛素+糖苷酶抑制剂(10.5%)及磺脲类+糖苷酶抑制剂(9.9%)。根据使用胰岛素与否,行多元回归分析发现:使用胰岛素与糖尿病病程正相关,与空腹C肽水平成负相关(均P<0.01)。结论 HbA_(lc)控制达标的患者多数需要联合用药。糖尿病病程越长,C肽水平越低,越需要使用胰岛素。
Objective To understand the medication control of patients with type 2 diabetes mellitus and to provide reference for clinical rational drug use. Methods Fasting plasma glucose and C-peptide were measured in 334 type 2 diabetic patients with HbA1c (6.5%). Diabetes drugs were also investigated. The distribution and frequency of the drugs were analyzed. Results Among 334 patients with HbA_ (1c), the most frequently used drug was glycosidase inhibitor (49.7%). In all patients 56.6% (189/334) were combined. The most common combination regimens are: premixed insulin + glycosidase inhibitors (10.5%) and sulfonylureas + glycosidase inhibitors (9.9%). Multivariate regression analysis showed that the use of insulin was positively correlated with the course of diabetes and negatively correlated with the level of fasting C-peptide (all P <0.01). Conclusion The majority of HbA_ (lc) control patients need combination therapy. The longer the duration of diabetes, the lower the level of C-peptide, the more you need to use insulin.